- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02770430
Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease
A Phase II, Randomized Study to Evaluate the Human Mesenchymal Stem Cells as a First-line Treatment for aGVHD in Patients Steroids Resistant.
Steroids are still the first line treatment for established severe acute-graft-versus-host-disease (aGVHD), with a response rate of 30-50%, and there is no established and effective therapy for severe steroid-refractory (aGVHD). The outcome for patients is poor and overall survival low, with few patients alive at 2 years.
In the case of failure after corticosteroid treatment, different therapeutic options have been introduced as second or third-line strategies. In this scenario, infusion of ex vivo expanded mesenchymal stromal cells (MSCs) has emerged as an additional tool for treatment of GVHD.
The purpose of this work is conduct a study in patients with refractory and/or resistant GVHD corticosteroids treatment. It will be randomized into two groups: one group that will receive the MSCs and the other group will follow the acute GVHD steroid-resistant and/or refractory treatment according to the routines of the Bone Marrow Transplantation (BMT) service of Hospital de Clinicas de Porto Alegre. It will be evaluated aspects of immune recovery early after MSCs infusion.
연구 개요
상세 설명
Allogeneic hematopoietic stem cell transplant (AlloSCT) is the treatment of choice for many malignant and non-malignant hematological disorders. However, this treatment is frequently complicated by acute graft-versus-host-disease (aGVHD), wich can be associated with high morbidity and mortality.
Steroids are still the first line treatment for established aGVHD, with a response rate of 30-50%, and there is no established and effective therapy for severe steroid-refractory aGVHD. The outcome for patients is poor and overall survival low, with few patients alive at 2 years.
In the case of failure after corticosteroid treatment, different therapeutic options have been introduced as second or third-line strategies. In this scenario, infusion of ex vivo expanded mesenchymal stem cells (MSCs) has emerged as an additional tool for treatment of GVHD.
MSCs are non hematopoietic multipotent cells with self-renewal properties and the ability to differentiate into mesenchymal tissues. Several lines of evidence in the past few years have confirmed the ability of theses cells differentiate into cells derived form embryonic mesoderm, such as osteocytes, adipocytes and chondroblasts. In vitro, culture-expanded MSCs express membrane antigens that can be immunophenotyped by flow cytometry. The most widely accepted antigen expression pattern is cluster of differentiation (CD) 29, CD105, CD73, and CD90 positivity in 97 % of cells and minimal expression of CD45, CD34, CD3, CD14, CD19, or human leukocyte antigen (HLA) -DR, which should be positive in less than 3 % of cells.
Because they are easy to isolate and culture and due to their differentiation potential and production of growth factors and cytokines, MSC have become ideal candidates for regenerative protocols.
The purpose of this work is conduct a study in patients with refractory and/or resistant GVHD corticosteroids treatment. It will be randomized into two groups: one group that will receive the MSCs and the other group will follow the acute GVHD steroid-resistant and/or refractory treatment according to the routines of the Bone Marrow Transplantation service of Hospital de Clinicas de Porto Alegre. It will be evaluated aspects of immune recovery early after MSCs infusion.
METHOD: This is a prospective, randomized, controlled, open label study to evaluate the effectiveness of early treatment of steroid-resistant acute GVHD with MSC. All patients with refractory and/or resistant steroids GVHD will be included after signing of free and informed consent.
After randomization, patients will be allocated to receive conventional treatment:
- Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.
- If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR.
Patients in the study group will receive two infusions of MSC per week during two weeks and 1 more MSC infusion (2 + 2 + 1 scheme).
After 28 days, if VGPR is not obtained, crossover between groups will be allowed as well as for the patients with progressive GVHD in spit of treatment arm, before day +28. The latter group of patients, who use both treatments (MSC + Conventional treatment) before day + 28 will be analyzed separately.
Bone marrow (BM) derived MSCs from normal BMT donors (third part) will be isolated and expanded under conditions of Good Manufacturing Practice. The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests.
Patients response evaluation will be at Day + 28:
- Complete response: disappearance of all symptoms
- Partial response: with a decrease at least of one degree of GVHD
- VGPR: decrease to the stage I of GVHD
- Stable disease: when there is a stability of the disease
- Number and type of infection in the first 100 days after transplant
The transplant-related mortality, disease-free survival, overall survival and the development of chronic GVHD or not, will also be evaluated.
연구 유형
등록 (예상)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Lucia Silla, PhD
- 전화번호: 55 51 33597516
- 이메일: dralucia.silla@gmail.com
연구 연락처 백업
- 이름: Vanessa Valim, Msc
- 전화번호: 55 51 33598850
- 이메일: vanessavalim@gmail.com
연구 장소
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, 브라질, 90035-903
- 모병
- Centro Terapia e Tecnologia Celular
-
연락하다:
- Lucia Silla, PhD
- 전화번호: 55 51 33597516
- 이메일: dralucia.silla@gmail.com
-
연락하다:
- Vanessa Valim, Msc
- 전화번호: 55 51 33598850
- 이메일: vanessavalim@gmail.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- All patients with refractory and/or resistant steroids GVHD will be included after signing of free and informed consent.
Exclusion Criteria:
- They will be excluded from the study, patients who did not agree to participate and don't sign an informed consent (which is going to receive conventional treatment) and that patients who is a Grade I refractory GVHD.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
활성 비교기: conventional treatment
After randomization, patients will be allocated to receive conventional treatment:
|
다른 이름들:
|
실험적: mesenchymal stem cells
Patients in the study group will receive two infusions of MSC per week during two weeks and 1 more MSC infusion (2 + 2 + 1 scheme).
Dosage: 2x10E6/Kg
|
MSCs derived from bone marrow (BM) will be isolated and expanded in the laboratory under conditions of Good Manufacturing Practice.
The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests.
Patients will receive five infusions of MSC.
Dosage: 2x10E6 cells/Kg
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
Complete response: disappearance of all symptoms
기간: It will be evaluated the patients response who received MSC infusion or conventional therapy in the 28th day of the study.
|
It will be evaluated the patients response who received MSC infusion or conventional therapy in the 28th day of the study.
|
2차 결과 측정
결과 측정 |
기간 |
---|---|
Partial response: with a decrease at least of one degree of GVHD
기간: It will be evaluated the patients response who received MSC infusion or conventional therapy in the 28th day of the study.
|
It will be evaluated the patients response who received MSC infusion or conventional therapy in the 28th day of the study.
|
VGPR: decrease to the stage I of GVHD
기간: It will be evaluated the patients response who received MSC infusion or conventional therapy in the 28th day of the study.
|
It will be evaluated the patients response who received MSC infusion or conventional therapy in the 28th day of the study.
|
Stable disease: when there is a stability of the disease (by Clinical evaluation)
기간: It will be evaluated the patients response who received MSC infusion or conventional therapy in the 28th day of the study.
|
It will be evaluated the patients response who received MSC infusion or conventional therapy in the 28th day of the study.
|
Number of infection (by Clinical and laboratory evaluation)
기간: First 100 days after transplant
|
First 100 days after transplant
|
Type of infection (by Clinical and laboratory evaluation)
기간: First 100 days after transplant
|
First 100 days after transplant
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Lucia S Silla, Hospital de Clinicas de Porto Alegre
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 12-0407
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
conventional treatment에 대한 임상 시험
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...모병
-
Memorial Sloan Kettering Cancer Center종료됨
-
Guangdong Provincial People's Hospital아직 모집하지 않음만성 골수성 백혈병 | 무치료 관해
-
University of Glasgow완전한
-
Ospedale Generale Di Zona Moriggia-Pelascini완전한
-
University of Alabama at Birmingham모병
-
University Hospital Inselspital, BerneBoston Scientific Corporation종료됨
-
Zealand University HospitalUniversity of Copenhagen; Steno Diabetes Center Copenhagen; Holbaek Sygehus모병